55144-54-2

Basic information

• Product Name: 2-BROMO-6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-ONE
• Synonyms: 2-BROMO-6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-ONE
• CAS NO: 55144-54-2
• Molecular Formula: C9H6BrClO
• Molecular Weight: 245.5
• Mol File: 55144-54-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 324.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.737±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-BROMO-6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-ONE(55144-54-2)
• EPA Substance Registry System: 2-BROMO-6-CHLORO-2,3-DIHYDRO-1H-INDEN-1-ONE(55144-54-2)

Safety Data

• Hazardous Substances Data: 55144-54-2(Hazardous Substances Data)

Upstream product

• 14548-38-0 6-chloro-1-indanone 

Relevant articles and documents

Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives

In our efforts to discover more potent and lasting NHE1 inhibitors, we designed and synthesized a series of substituted indan-1-ylidene aminoguanidine derivatives (5). NHE1 inhibitory activity of twenty-one compounds 5 was evaluated in a rat platelet swelling assay. It is found that most of the tested compounds possess NHE1 inhibitory effects. 2-(5-methoxybenzimidazol-2-ylthio)-5-chloro-2,3-dihydroinden-1-ylidene aminoguanidine hydrobromide (5m) proved to be sixty-nine times more potent than cariporide. Furthermore, when tested in vivo, compound 5m also displayed superior cardioprotective effects against SD rat myocardial ischemic-reperfusion injury over those of cariporide.

IMIDAZO(1,2-A)-INDENO (1,2-E) PYRAZIN-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Pharmaceutical compositions containing, as the active principle, compounds of formula (I): STR1 wherein R, R 1 and R. sub.2 are as defined in the description, or salts thereof, the novel compounds of formula (I), and the preparation thereof. The compounds of formula (I) have valuable pharmacological properties and are alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, this receptor also being known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive N-methyl-D-aspartate (NDMA) receptor antagonists, and particularly NMDA receptor glycine modulation site ligands.